drugset / Trial / NCT07177079
High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)
RandomizedSingle-groupOpen-labelTreatment
Summary
This is a randomized, open-label, Phase I clinical study with expansion. It will assess the safety and efficacy of high-dose ascorbate administered concomitantly with azacitidine and venetoclax in newly diagnosed AML.
Timeline
- Start
- 2026-03-18
- Primary completion
- 2028-12-31
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vitamin C | Other / unclassified | — | Intravenous |
| Background | Azacitidine | Other / unclassified | — | — |
| Background | Decitabine | Small molecule | 20 mg/m2 | — |
| Background | Venetoclax | Small molecule | — | — |